Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer-How to Identify Patients...

Area of Science:

• Oncology
• Thoracic Oncology
• Cancer Treatment

Background:

• Consolidation systemic therapy (ST) is frequently administered after concurrent chemoradiotherapy (CRT) in locally advanced, inoperable non-small cell lung cancer (NSCLC).
• The clinical significance of patient response to the initial concurrent phase of treatment remains poorly understood.
• Optimal patient selection for consolidation ST is challenging due to limited data on response-specific outcomes.

Purpose of the Study:

• To evaluate the available literature on the outcomes of patients with non-small cell lung cancer (NSCLC) based on their response to initial concurrent chemoradiotherapy (CRT).
• To identify patterns of failure and survival data stratified by response after the concurrent phase of treatment.
• To assess the impact of response assessment on the decision-making process for consolidation systemic therapy (ST).

Main Methods:

• A systematic literature search was conducted for Phase II and III clinical studies involving consolidation ST after concurrent CRT in NSCLC.
• Studies were screened for information on response evaluation after the concurrent phase and subsequent patient outcomes.
• Data extraction focused on response subgroups, patterns of failure, and survival outcomes.

Main Results:

• Out of 87 initially identified articles, 67 were included in the analysis.
• Response evaluation after the concurrent phase was reported in 54% of studies, but detailed response data was available in only 21%.
• Crucially, no studies provided outcome data (survival, patterns of failure) stratified by response achieved after the concurrent phase.

Conclusions:

• There is a significant lack of information regarding the outcomes of NSCLC patients based on their response to initial CRT before consolidation ST.
• This data gap impedes the ability to determine which patients may benefit most from consolidation ST.
• Further research is needed to provide response-specific outcome data to guide clinical decision-making in NSCLC treatment.